Evaluation of the efficacy and tolerability of acarbose in patients with diabetes mellitus a postmarketing surveillance study

Clinical Drug Investigation

Volumn 25, Issue 10, 2005, Pages 651-659

  Spengler, M ^a,b   Schmitz, H ^a   Landen, H ^a  

^a BAYER AG   (Germany)

^b NONE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACARBOSE; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C; INSULIN; METFORMIN; ORAL ANTIDIABETIC AGENT; SULFONYLUREA;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BLOOD GLUCOSE MONITORING; BODY MASS; BODY WEIGHT; CONTROLLED STUDY; DIARRHEA; DIET THERAPY; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; FLATULENCE; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; LIVER DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL;

EID: 24944497145     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-200525100-00004     Document Type: Article

References (15)

1. Lebovitz HE. α-Glucosidase inhibitors as agents in the treatment of diabetes. Diabetes Rev 1998; 6: 132-45
2. Spengler M, Cagatay M. Bewertung der Wirksamkeit und Verträglichkeit von Acarbose durch Anwendungsbeobachtung. Diab Stoffw 1992; 1: 218-22
3. Braun H, Belser F. Inhibiteur de l'alpha-glucosidase chez le diabétique. Efficacité et tolérance de l'acarbose en practique courante. DIA/GM (Swiss) 1994; 9: 654-6
4. Spengler M, Cagatay M. The use of acarbose in the primarycare setting: evaluation of efficacy and tolerability of acarbose by postmarketing surveillance study. Clin Invest Med 1995; 18: 325-31
5. Bergamini L, Cocilov L, Giorgino R, et al. Acarbose in noninsulin-dependent diabetic patients in routine clinical practice: results from a multicentre study. Ann Exp Clin Med 1997; 1-2: 45-51
6. Mertes G. Efficacy and safety of acarbose in the treatment of type 2 diabetes: data from a 2-year surveillance study. Diabetes Res Clin Pract 1998; 40: 63-70
7. Buse J, Hart K, Minasi L. The PROTECT Study: final results of a large multicenter postmarketing study in patients with type 2 diabetes. Clin Ther 1998; 20: 257-69
8. Mertes G. Safety and efficacy of acarbose in the treatment of type 2 diabetes: data from a 5-year surveillance study. Diabetes Res Clin Pract 2001; 52: 193-204
9. Standl E. Die Angiopathien des Typ-2-Diabetes. Verh Dtsch Ges Inn Med 1986; 92: 579-86
10. Standl E, Stiegler H, Janka HU, et al. Risk profiles of macrovas-cular diseases in diabetes mellitus. Diab Med 1988; 14: 505-11
11. Nationale Versorgungsleitlinie Diabetes mellitus Typ 2, 1. Auflage Mai 2002, ÄZQ-Redaktion Versorgungsleitlinien, Aachener Str. 233-237, D-50931 Köln
12. Laube H. Acarbose: an update of its therapeutic use in diabetes treatment. Clin Drug Invest 2002; 22: 141-56
13. Breuer HWM. Review of acarbose therapeutic strategies in the long-term treatment and in the prevention of type 2 diabetes. Int J Clin Pharmacol Ther 2003; 41: 421-40
14. Van de Laar FA, Lucassen PL, Akkermans RP, et al. α-Glucosidase inhibitors for patients with type 2 diabetes: results from a Cochrane systematic review and meta-analysis. Diabetes Care 2005; 28: 154-63
15. Hollander PA. Acarbose: adverse events and safety profile. Drug Benefit Trends 1996; (Suppl E) 8: 46-54